Metastatik meme kanserinin tedavisinde capecitabine: Etkinlik ve toksisite
Küçük Resim Yok
Tarih
2003
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Capecitabine, devamlı 5-fluorouracil infüzyonuna benzer etkiye sahip oral fluoropirimidin' dir. Ağız yoluyla alınması ve venöz girişimle ilişkili komplikasyonlara yol açmaması nedeni ile hastalar ve tıbbi onkologlar için daha kullanışlıdır. Klinik çalışmalarda, öncesinde antrasiklin ve taksan kullanılmış metastatik meme kanserli hastaların tedavisinde Capecitabine' in etkinliği ve toleransının iyi olduğu gösterilmiştir. Bu çalışmada öncesinde antrasiklin ve taksan tedavisi uygulanmış, metastatik meme kanseri olan olgularda Capecitabine'in etkinliği ve toksisitesi retrospektif olarak değerlendirilmiştir. Capecitabine, toplam 42 hastaya her 3 haftalık tedavi siklusunun 1-14. günlerinde 2000 mg/m2/gün dozunda oral olarak uygulanmıştır. Tam yanıt yoktu. Kısmi yanıt oranı %19, stabil yanıt oranı %45,2 olarak hesaplandı. Medyan progresyonsuz sağkalım süresi 5 aydı. Ayrıca cerbB2 alt grup analizi yapıldı. Progresyonsuz sağkalım cerbB2 negatif olan grupta cerbB2 pozitif gruba göre iyiydi. İki grup arasındaki fark istatistiksel olarak anlamlıydı. Oral Capecitabine monoterapisi kabul edilebilir güvenlik profili gösterdi. Grad 3-4 yan etki görülme sıklığı düşüktü. Capecitabine tedavisi bu grup hastalarda antitümör aktiviteye ve kabul edilebilir güvenlik profiline sahiptir.
Capecitabine is an oral fluoropyrimidine that mimics continuous infusion 5-fluorouracil. As an oral agent, Capecitabine is more convenient for patients and medical oncologists, and avoids the complications associated with venous access. Clinical trials have demonstrated the efficacy and tolerability of Capecitabine in anthracycline and taxane pretreated metastatic breast cancer. In this study, we evaluated efficacy and tolerability of Capecitabine in anthracycline and taxane pretreated metastatic breast cancer retrospectively. A total of 42 patients received oral Capecitabine 2000 mg/mVdaily, on days 1-14 of each 3-week treatment cycle. Complete response not achieved. The partial and stable response rate were %19, %45,2 respectively. Median progression free survival time was 5 months. Additionally, cerbB2 subgroup analysis was performed. Progression free survival was longer in cerbB2 negative group than cerbB2 positive group. Difference between two groups was statistically significant. Oral Capecitabine monotherapy demonstrated an acceptable safety profile. There was a low incidence of grade 3-4 adverse event. Capecitabine therapy, has antitumor activity and an acceptable safety profile in this setting.
Capecitabine is an oral fluoropyrimidine that mimics continuous infusion 5-fluorouracil. As an oral agent, Capecitabine is more convenient for patients and medical oncologists, and avoids the complications associated with venous access. Clinical trials have demonstrated the efficacy and tolerability of Capecitabine in anthracycline and taxane pretreated metastatic breast cancer. In this study, we evaluated efficacy and tolerability of Capecitabine in anthracycline and taxane pretreated metastatic breast cancer retrospectively. A total of 42 patients received oral Capecitabine 2000 mg/mVdaily, on days 1-14 of each 3-week treatment cycle. Complete response not achieved. The partial and stable response rate were %19, %45,2 respectively. Median progression free survival time was 5 months. Additionally, cerbB2 subgroup analysis was performed. Progression free survival was longer in cerbB2 negative group than cerbB2 positive group. Difference between two groups was statistically significant. Oral Capecitabine monotherapy demonstrated an acceptable safety profile. There was a low incidence of grade 3-4 adverse event. Capecitabine therapy, has antitumor activity and an acceptable safety profile in this setting.
Açıklama
Anahtar Kelimeler
Onkoloji
Kaynak
Türk Hematoloji Onkoloji Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
13
Sayı
4
